Citi lowered the firm’s price target on Solid Biosciences (SLDB) to $14 from $16 and keeps a Buy rating on the shares following data from the Phase 1/2 INSPIRE-DUCHENNE trial. The firm says microdystrophin expression after 90 days dropped.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences Faces Regulatory and Financial Challenges Amid FDA Disruptions
- Solid Biosciences’ SGT-003 Therapy Shows Promising Efficacy and Safety, Earning a Buy Rating
- Solid Biosciences price target lowered to $9 from $10 at Barclays
- Solid Biosciences Reports Q3 2025 Results and Clinical Progress
- Solid Biosciences Reports Positive Interim Data on SGT-003